Motifene Dual (Diclofenac Sodium)

Diclofenac Sodium acts on inflammatory pathways to reduce pain and swelling in several musculoskeletal disorders.

• Osteoarthritis: alleviates joint pain and improves functional mobility.
• Rheumatoid arthritis: decreases synovial inflammation and joint tenderness.
• Musculoskeletal pain: provides analgesic relief for sprains, strains, and low‑back discomfort.

• Diclofenac Sodium non‑selectively inhibits cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which blocks the conversion of arachidonic acid to prostaglandins. The reduced prostaglandin synthesis diminishes inflammation, pain signaling, and fever responses at the site of tissue injury.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Gastrointestinal discomfort or dyspepsia
• Nausea or vomiting
• Headache
• Dizziness
• Skin rash or pruritus
• Elevated liver enzymes

Serious or Rare Side Effects

• Gastrointestinal ulceration or bleeding
• Hepatic injury or jaundice
• Acute renal failure or reduced kidney function
• Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome)
• Cardiovascular events such as myocardial infarction
• Anaphylactic or severe allergic reactions

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

• Renal function: assess baseline creatinine and adjust use in renal impairment.
• Hepatic health: monitor liver enzymes, especially with prolonged treatment.
• Gastrointestinal risk: avoid in patients with active peptic ulcer disease or a history of GI bleeding.
• Concomitant anticoagulants: use the lowest effective dose and monitor coagulation parameters.
• Cardiovascular caution: consider risk in patients with established heart disease.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Diclofenac Sodium can alter the pharmacokinetics or pharmacodynamics of several co‑administered medicines.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased bleeding risk.
• Lithium: elevated serum lithium levels.
• Methotrexate: reduced clearance leading to toxicity.
• SSRIs (e.g., sertraline): heightened gastrointestinal bleeding.
• ACE inhibitors (e.g., enalapril): possible reduction in renal function.

Moderate Interactions (Monitor Closely)

• Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity.
• Diuretics (e.g., furosemide): potential renal impairment.
• Beta‑blockers: may blunt antihypertensive effect.
• Corticosteroids: increased risk of ulceration.
• Cyclosporine: enhanced nephrotoxicity.